Mironid raises USD 46 million in Series B led by Scottish National Investment Bank, backed by Sofinnova Partners

PUBT · 1d ago
Mironid raises USD 46 million in Series B led by Scottish National Investment Bank, backed by Sofinnova Partners
  • Mironid raised USD 46 million in a Series B round to fund clinical development of its lead therapy for autosomal dominant polycystic kidney disease.
  • The Glasgow-based biotech develops first-in-class small molecules designed to directly target cyclic AMP, a driver of cyst growth in ADPKD.
  • Scottish National Investment Bank joined the round alongside existing backers including Sofinnova Partners.
  • Proceeds will support clinical advancement of Mironid’s LoAc small-molecule candidate in ADPKD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.